Travere Therapeutics (TVTX) Bank of America Global Healthcare Conference 2026 summary

Company overview and recent developments

• Focused on rare kidney diseases, with innovative therapies for IgA nephropathy and FSGS, and a phase III program in classical homocystinuria.

• Recently received FDA approval for FILSPARI in FSGS, marking the first approved therapy for this progressive disease.

• FILSPARI is positioned as foundational therapy, with strong physician and patient community support.

• Early launch feedback is overwhelmingly positive, with high initial demand and rapid inclusion in payer formularies.

• Addressable patient populations are expected to grow with increased awareness and earlier diagnosis.

Market dynamics and launch strategy

• FILSPARI replaces ACE inhibitors or ARBs for incident FSGS patients and is expected to be an anchor therapy.

• Uptake in FSGS is anticipated to be faster than in IgA nephropathy due to higher unmet need and established brand equity.

• Prescriber overlap between FSGS and IgAN is significant, reducing the need for incremental education.

• Early payer feedback is positive, with higher first-pass approval rates for FSGS compared to IgAN.

• Steady, linear uptake is expected due to the quarterly frequency of FSGS patient visits.

Industry trends and future outlook

• First-to-market advantage for FILSPARI is significant, with a long lead time before potential competitors arrive.

• Additional therapies are seen as complementary, expanding the market and accelerating innovation.

• Earlier intervention and diagnosis are emphasized as key to improving patient outcomes.

• Proteinuria is now widely accepted as a surrogate endpoint, supporting earlier and more aggressive treatment.

• Combination approaches and lower treatment targets are becoming standard, mirroring trends in other specialties.